Japanese Domestic Tobacco Business: Volume and market share are recovering steadily from the effects of the earthquake. The volume decline is also due to the prior year’s tax and price increase and unfavourable comparison as a result of heightened demand
International Tobacco Business: Profit growth was driven by strong pricing and GFB shipment volume growth. Market share2 continued to increase in most key markets
Pharmaceutical Business: Anti-HIV single-tablet regimen containing JTK-303 was submitted for U.S. FDA approval, JT's partner, Gilead Sciences, has announced
Results for the 6 months ended September 30, 2011
Adjusted net sales and EBITDA declined by 8.7% and 3.6% respectively due to the negative impact of the earthquake on the Japanese domestic tobacco business. Net income increased by 17.9% as a result of improved currency exchange gains and losses and reduced tax expenses
Japanese Domestic Tobacco Business’ adjusted net sales, EBITDA and sales volume decreased by 20.5%, 9.7% and 41.2% respectively. The business is steadily recovering from the effects of the earthquake as the number and volume of products shipped sequentially increased following resumption of shipments after the earthquake
International Tobacco Business again delivered a strong performance with core net sales growth of 9.3% and EBITDA growth of 14.6% in US dollars. At constant rates of exchange, core net sales and EBITDA increased 6.2% and 13.3% respectively